Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

This trial tests a CAR-T cell therapy called CNCT19 — a treatment where your own immune cells are engineered to attack leukemia cells — in adults with acute lymphoblastic leukemia (ALL) that has come back or stopped responding to standard treatment. **You may be eligible if...** - You are between 18 and 65 years old - You have relapsed or treatment-resistant (refractory) ALL - Your leukemia cells carry a protein called CD19 on their surface - Your cancer came back within 12 months of first remission, or did not respond to at least two rounds of chemotherapy, or returned after a bone marrow transplant **You may NOT be eligible if...** - Your leukemia cells do not express CD19 - You are under 18 or over 65 - You have conditions that prevent you from safely receiving this therapy Talk to your doctor to see if this trial is right for you.